Novel OACs

Question 1

Three NOACs (?, ? and ?) have been approved by NICE for ? prevention in patients with ?.
o ? and ? are reversible competitive antagonists of factor Xa (Xa-ban).
o ? is a reversible competitive antagonist of thrombin (Ila).

Answer 1

dabigatran, rivaroxaban, apixaban
secondary
AF
rivaroxaban, apixaban
dabigatran

Question 2

Their main advantages are a ? ? of anticoagulant effect, more ? pharmacokinetics, and a lower potential for clinically important ? with ?, lifestyle and other ?.
There is no need for ? coagulation ?

Answer 2

rapid onset
predictable
interactions
food
drugs
routine
monitoring

Question 3

Trial data shows decreased rates of ? bleeding with these drugs,
and ‘real world’ data also seems to support this.
For ? and ? there may be a slight increased risk of ? bleeding compared to warfarin.

Answer 3

intracranial
dab
riv
GI

Question 4

There are as yet ? specific antidotes for the NOACs, but there are steps that
can be taken in the event of a ? bleed.
—0 Use prothrombin complex concentrate (?).

Answer 4

no
major
otaplex

Question 5

They are partially cleared by the ? (dose reduction in ?).

Answer 5

kidney

CKD

Question 6

For surgery, ? anticoagulation is generally not required due to the predictable dose reductions of these drugs, and ? ? once re-started.

Answer 6

bridging

rapid onset